Pages that link to "Q33358394"
Jump to navigation
Jump to search
The following pages link to Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study (Q33358394):
Displaying 50 items.
- Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy (Q24814325) (← links)
- The cilia-regulated proteasome and its role in the development of ciliopathies and cancer (Q26746930) (← links)
- Role of the ubiquitin proteasome system in renal cell carcinoma (Q33307879) (← links)
- Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. (Q33378628) (← links)
- A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy (Q33380300) (← links)
- Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma (Q33388541) (← links)
- An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. (Q33391857) (← links)
- Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. (Q33401308) (← links)
- Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab (Q33418562) (← links)
- Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies (Q33421241) (← links)
- Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies (Q33745227) (← links)
- The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib. (Q33916030) (← links)
- Novel approaches in the therapy of metastatic renal cell carcinoma. (Q34409187) (← links)
- Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitors (Q34532897) (← links)
- IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis (Q34598755) (← links)
- Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent (Q34610605) (← links)
- Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options (Q35000792) (← links)
- Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice (Q35175035) (← links)
- Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo (Q35856827) (← links)
- The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy (Q36066214) (← links)
- Anaplastic thyroid carcinoma (Q36075843) (← links)
- Proteasome inhibition as a therapeutic strategy for hematologic malignancies (Q36185620) (← links)
- CIP2A is a target of bortezomib in human triple negative breast cancer cells (Q36245640) (← links)
- Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies (Q36264209) (← links)
- Emerging drugs for renal cell carcinoma (Q36302842) (← links)
- Pulmonary toxicity from novel antineoplastic agents (Q36314452) (← links)
- An approach to evaluating drug-nutrient interactions (Q36320632) (← links)
- The proteasome: a novel target for anticancer therapy (Q36499578) (← links)
- Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. (Q36529784) (← links)
- New drug therapies for advanced renal cell carcinoma (Q36691810) (← links)
- The unfolded protein response and cancer: a brighter future unfolding? (Q36704651) (← links)
- Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells (Q36805842) (← links)
- Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI. (Q36807352) (← links)
- Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells (Q36857564) (← links)
- Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer (Q36920440) (← links)
- Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. (Q37004739) (← links)
- The role of the NFkappaB signalling pathway in cancer (Q37102767) (← links)
- In vivo imaging, tracking, and targeting of cancer stem cells (Q37305741) (← links)
- BU-32: a novel proteasome inhibitor for breast cancer (Q37467249) (← links)
- The development and pharmacology of proteasome inhibitors for the management and treatment of cancer (Q37709559) (← links)
- Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I. (Q37882459) (← links)
- Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance (Q38739048) (← links)
- CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells (Q39664633) (← links)
- Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. (Q40025076) (← links)
- Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. (Q40362170) (← links)
- Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases (Q40380082) (← links)
- VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. (Q40479170) (← links)
- Proteasome inhibitor treatment in alcoholic liver disease (Q41788715) (← links)
- Cancer stem cells don't waste their time cleaning-low proteasome activity, a marker for cancer stem cell function (Q42330818) (← links)
- Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN (Q42355050) (← links)